Core Viewpoint - The company, Zhenbao Island, faced criticism from the Shanghai Stock Exchange for failing to timely disclose a significant transaction that generated a net profit of approximately 420 million yuan, which accounted for 227% of its audited net profit for 2022 [1][2][3] Group 1: Transaction Details - The undisclosed transaction involved the sale of 100% equity of its subsidiary, Hulin Fangsheng Pharmaceutical Technology Co., which was sold for 425 million yuan to Heilongjiang Hehui Pharmaceutical Co. [2][3] - The transaction's profit exceeded the threshold requiring shareholder approval and timely disclosure, as it represented over 50% of the company's audited net profit for the previous year [2][3] Group 2: Regulatory Issues - This is not the first instance of Zhenbao Island facing issues related to information disclosure; the company has received warnings and criticisms from regulators multiple times in the past two years for similar violations [4] - In April 2024, the company was issued a warning by the Heilongjiang Securities Regulatory Bureau for failing to disclose a related party transaction involving 80 million yuan in non-operating fund occupation [4] Group 3: Financial Performance - Zhenbao Island reported revenues of 4.2 billion yuan, 3.1 billion yuan, and 2.7 billion yuan for the years 2022, 2023, and 2024 respectively, with a net profit of 753 million yuan in Q1 of the current year, down from 2.9 billion yuan in the same period last year [5] - The decline in Q1 performance was attributed to the postponement of the third batch of national traditional Chinese medicine procurement, which affected sales and profits [5]

据《新京报》5月6日报道，安徽阜阳一名患者因头晕接受刺五加注射液治疗后，出现意识模糊等症状， 最后经抢救无效死亡。 从开始输液到抢救无效死亡仅约2小时，目前患者家属已要求封存病历，进行尸检。阜阳市卫生健康 委、阜阳市中医医院同步启动事件调查，正在开展尸检，具体死亡原因等待调查。 此类中药注射液引发不良反应的案例并不鲜见。四川省药品不良反应监测中心此前的研究数据显示，刺 五加注射液近半数不良反应集中在用药后30分钟内，严重不良反应主要为过敏样反应、过敏性休克、哮 喘，甚至出现患者死亡等。 医药魔方统计数据显示，2023年刺五加注射液以6.14亿元的销售额位居中药注射液前列。 面对部分中药注射剂安全性争议，国家药监局近年频繁修订说明书。例如，炎琥宁注射剂已被标注"接 受本品治疗的患者有发生严重过敏反应的风险，包括过敏性休克，严重者可导致死亡"的黑框警示。 北京中医药大学卫生健康法治研究与创新转化中心主任邓勇告诉21世纪经济报道记者，中药注射剂是中 药现代化的一种探索形式，它在危急重症的治疗等方面有一定的作用和优势，如在一些感染性疾病、心 脑血管疾病的治疗中能发挥独特疗效。 "然而，其确实存在安全性隐患。不能因噎废 ...